How Do You Know If Tagrisso Is Working?
Written by Dr. Zack Ferris in TheSkyMeds Editorial Standards
Medically reviewed by Jonathan Reed, Medical Content Reviewer Oct 5 2026
If you are wondering how to know if Tagrisso is working, the clearest answer usually comes from follow-up imaging rather than symptoms alone. Tagrisso (osimertinib) is an EGFR-targeted treatment used in several settings for certain EGFR-mutated non-small cell lung cancers (NSCLC), so “working” can mean different things depending on why you are receiving it. In metastatic disease, doctors may look for tumor shrinkage, stable tumors, and no new cancer sites. After surgery, there may be no visible cancer to measure, so success is judged mainly by whether the cancer remains from recurring. Symptoms such as less coughing, pain, or breathlessness can be encouraging, but they cannot confirm treatment response by themselves. Regular scans, clinical assessment, and appropriate safety monitoring provide the most reliable picture of how treatment is going.
What Does It Mean for Tagrisso to Be Working?
Tagrisso is considered effective when it is achieving the goal for which it was prescribed. That goal is not always to make a visible tumor disappear.
The current FDA-approved Tagrisso prescribing information includes osimertinib for several EGFR-mutated NSCLC settings: after complete surgical removal of eligible tumors, after chemoradiation for certain unresectable stage III cancers, and for certain locally advanced or metastatic cancers. Treatment duration and the way effectiveness is assessed therefore differ by setting.
What “Tagrisso Is Working” Can Mean in Different Treatment Settings
Treatment setting | What doctors are trying to achieve | What may indicate treatment is working |
After surgery (adjuvant treatment) | Reduce the risk of cancer returning | Follow-up shows no evidence of recurrence |
Unresectable stage III disease after chemoradiation | Delay or prevent progression | Scans continue to show no disease progression |
Locally advanced or metastatic disease | Shrink cancer or keep it controlled | Tumors shrink or remain stable and no convincing new cancer sites appear |
Cancer involving the brain | Control intracranial as well as other disease | Brain imaging shows shrinkage or stability without new CNS progression |
In advanced disease, tumor shrinkage is clearly encouraging, but shrinkage is not the only successful outcome. Keeping cancer stable for a meaningful period can also indicate that treatment is controlling the disease.
The NCI non-small cell lung cancer treatment guidance summarizes randomized-trial evidence showing that osimertinib can delay disease progression in EGFR-mutated NSCLC and has activity against disease in the central nervous system.
You do not need every tumor to disappear for Tagrisso to be benefiting you. In advanced cancer, a scan showing that tumors have stopped growing and no new lesions have appeared can represent meaningful disease control.
How to Know If Tagrisso Is Working: What Do Scans Show?
Imaging is the main objective way doctors determine whether measurable cancer is responding to Tagrisso. CT scans are commonly used to compare tumors with their size before treatment, while MRI is particularly important when the brain needs assessment.
Oncologists look at more than one spot. They compare measurable tumors, other known cancer sites, lymph nodes, and any areas that appear new.
What does tumor shrinkage mean?
Shrinking tumors generally indicate a response to treatment. In cancer studies, standardized RECIST criteria are often used to describe response objectively.
The RECIST 1.1 response criteria define a partial response as at least a 30% decrease in the summed diameters of selected target lesions. Complete response means disappearance of target lesions, subject to specific criteria for lymph nodes.
Clinical care is more individualized than applying one percentage to every scan. Your oncologist also considers non-measurable disease, symptoms, previous imaging, and where the cancer is located.
Can stable disease mean Tagrisso is working?
Yes. Stable disease means the cancer has neither shrunk enough to meet the definition of a partial response nor grown enough to meet criteria for progression.
For metastatic cancer, preventing tumors from growing can be a meaningful treatment benefit. A scan that says “stable disease” should therefore not automatically be interpreted as treatment failure.
What suggests disease progression?
Clear enlargement of existing tumors or convincing new cancer lesions can indicate progression. Under RECIST 1.1, progression of measurable target lesions generally requires at least a 20% increase from the smallest recorded total, plus an absolute increase of at least 5 mm; definite new lesions can also represent progression.
Small or uncertain changes sometimes require careful radiology review or repeat imaging rather than an immediate conclusion that Tagrisso has stopped working.
Can Your Symptoms Tell You Whether Tagrisso Is Working?
Improving symptoms can support the overall picture, but symptoms alone cannot reliably prove that Tagrisso is controlling the cancer. Someone may feel better before a scan documents response, while another person may have stable cancer without noticing a dramatic physical change.
Possible encouraging changes can include:
Less coughing or chest discomfort.
Easier breathing.
Reduced cancer-related pain.
Improved appetite or energy.
Better ability to perform normal activities.
Improvement in neurological symptoms when brain metastases are responding.
These improvements are not specific to tumor response. Pain medicines, treatment of an infection, drainage of fluid around the lung, radiation, steroids, or other interventions can also make symptoms better.
The reverse is equally important. Fatigue, diarrhea, skin changes, or other side effects do not mean the cancer is getting worse.
Does getting a rash mean Tagrisso is working?
No. A rash can occur with EGFR-targeted medicines, but developing a rash is not a reliable personal test of whether Tagrisso is controlling your cancer.
Similarly, having very few side effects does not mean the drug has stopped working. Treatment effectiveness should be assessed through scans and clinical follow-up rather than by trying to judge the severity of side effects.
What if you feel better but the scan looks worse?
The scan generally carries greater weight when determining whether measurable cancer has progressed, but the entire clinical picture still matters. Radiologists and oncologists may review whether a suspected new lesion is definitely cancer and whether progression is limited to one area or occurring more broadly.
Do not stop Tagrisso because of symptoms or a scan report without discussing the result with your oncology team.
Can Blood Tests or ctDNA Show Whether Tagrisso Is Working?
Routine blood tests are important during cancer treatment, but most cannot directly tell whether Tagrisso is shrinking a tumor. Blood counts and chemistry tests are generally used to monitor overall health and treatment safety rather than to replace imaging.
Circulating tumor DNA, or ctDNA, is different. It examines fragments of tumor-derived DNA circulating in the bloodstream and can sometimes detect EGFR mutations and other molecular changes.
Research is evaluating whether changes in plasma EGFR mutations and ctDNA can help monitor treatment response earlier than conventional imaging. NCI-listed clinical studies are actively investigating clearance or persistence of plasma EGFR mutations during osimertinib treatment, showing that this remains an evolving area rather than a universal replacement for scans.
A falling or undetectable ctDNA result can be encouraging in the appropriate context, but it should not be interpreted alone. Some tumors release very little DNA into the bloodstream, so a negative result does not prove that all cancer has disappeared.
How Long Does It Take to Know Whether Tagrisso Is Working?
There is no single number of days after which everyone can know whether Tagrisso is working. Doctors usually compare scheduled follow-up imaging with the baseline scans obtained before or around the start of treatment.
Clinical trials illustrate why repeated imaging matters. In the LAURA study of unresectable stage III EGFR-mutated NSCLC after chemoradiation, tumor assessments were performed every eight weeks through week 48 and then every 12 weeks. That was a clinical-trial schedule, however, not a universal scanning timetable for every person taking Tagrisso.
Your oncologist may choose a different interval depending on:
Whether your cancer is early-stage, stage III, or metastatic.
Where cancer is located.
Whether brain metastases are present.
Your symptoms.
Previous scan results.
Other treatments you are receiving.
Whether an earlier scan is needed because something has changed.
Feeling better within the first few weeks may be encouraging, but only follow-up assessment can show whether the cancer itself has responded.
What If Your Scan Shows Stable, Mixed, or Unclear Results?
Not every scan produces a simple “working” or “not working” answer. Stable disease, small measurement differences, treatment-related changes, and different responses in different tumor sites can make interpretation more complicated.
What Common Follow-Up Scan Results May Mean During Tagrisso Treatment
Scan result | Possible interpretation | What may happen next |
Tumors are clearly smaller | Treatment response | Tagrisso may be continued if it remains appropriate and tolerable |
Tumors are about the same size | Stable disease; cancer may still be controlled | Continued treatment and scheduled monitoring may be appropriate |
One lesion grows while others remain controlled | Possible limited or oligoprogression | Additional imaging, biopsy, local treatment, or treatment-plan review may be considered |
Several lesions enlarge or new lesions appear | Broader disease progression may be developing | Oncologist may confirm progression and reassess systemic treatment |
Scan finding is uncertain | Could represent measurement variation, inflammation, treatment effect, or disease | Radiology review, shorter-interval imaging, another imaging method, or biopsy may be considered |
One growing lesion does not necessarily mean Tagrisso has completely lost activity everywhere. Some cancer-cell populations can become resistant while other sites remain controlled.
This is why oncologists sometimes describe progression as “limited” or “oligoprogressive” rather than simply saying the medicine has failed. The location, number of growing lesions, symptoms, and molecular findings can all influence the next decision.
What Should You Monitor While Taking Tagrisso?
Monitoring has two purposes: checking whether the cancer is controlled and making sure treatment remains safe. Follow-up may therefore include imaging, symptom review, medication review, blood tests, and selected cardiac monitoring.
Keep track of meaningful changes between appointments rather than waiting for the next scan. Note new pain, persistent cough, worsening breathlessness, neurological symptoms, appetite changes, unexplained weight loss, and changes in your ability to perform everyday activities.
Also take Tagrisso exactly as prescribed. The current U.S. prescribing information lists 80 mg once daily for approved adult indications, with duration depending on treatment setting; metastatic and unresectable stage III treatment generally continues until disease progression or unacceptable toxicity, while adjuvant therapy is given for up to three years or until recurrence or unacceptable toxicity.
Do not increase, decrease, stop, or restart Tagrisso based on how you feel without discussing it with your oncology team.
When Should New Symptoms Be Reported Promptly?
New symptoms during Tagrisso treatment should not automatically be interpreted as cancer progression. They can also result from treatment toxicity, infection, blood clots, other illnesses, or unrelated causes.
Contact your healthcare team promptly for new or worsening breathing problems, shortness of breath, cough, or fever. The current Tagrisso label warns that osimertinib can cause interstitial lung disease or pneumonitis, which can be severe and occasionally fatal.
Tagrisso can also affect the heart, including QTc prolongation and cardiomyopathy. People with relevant risk factors may require ECG, electrolyte, or heart-function monitoring during treatment.
Seek urgent or emergency assessment for severe breathing difficulty, coughing up significant blood, a seizure, sudden weakness, severe confusion, loss of consciousness, or rapidly worsening neurological symptoms.
Conclusion
The best way to understand how to know if Tagrisso is working is to look at the complete picture: follow-up scans, disease stability or shrinkage, absence of convincing new lesions, symptoms, and your oncologist's clinical assessment. Feeling better can be encouraging, but symptoms and side effects cannot confirm response by themselves.
Stable disease may still represent meaningful benefit, particularly in advanced cancer. Keep scheduled scans and appointments, take Tagrisso exactly as prescribed, and report new or worsening symptoms promptly. Your oncology team can explain what each scan means in the context of your EGFR mutation, cancer stage, and treatment goal.
Frequently Asked Questions
1. How soon can you tell if Tagrisso is working?
There is no universal timeframe. Response is usually assessed at scheduled follow-up imaging rather than from symptoms alone. Your oncologist determines scan timing based on cancer stage, disease sites, previous imaging, symptoms, and whether Tagrisso is being used alone or with other treatment.
2. Does stable disease mean Tagrisso is working?
Yes, it can. Stable disease means cancer has not shrunk enough to qualify as a partial response but has also not clearly progressed. In advanced NSCLC, preventing further tumor growth can represent meaningful treatment benefit.
3. Does feeling better mean Tagrisso is shrinking the cancer?
It may be an encouraging sign, but it does not prove tumor shrinkage. Symptoms can improve for several reasons unrelated to cancer response. Imaging and clinical assessment are needed to determine objectively whether Tagrisso is controlling the disease.
4. Does having no side effects mean Tagrisso is not working?
No. The absence of rash, diarrhea, or other side effects does not mean Tagrisso is ineffective. People experience drug side effects differently, and treatment response should be judged by cancer monitoring rather than how many adverse effects someone develops.
5. Can Tagrisso work even if the tumor does not shrink?
Yes. If tumors remain stable and no meaningful new disease appears, Tagrisso may still be controlling the cancer. Preventing growth can be an important treatment outcome in advanced NSCLC, even without a dramatic decrease in tumor size.
6. What happens if one tumor grows while the others shrink?
That may represent a mixed response or limited progression. Doctors assess the location and number of progressing sites and may consider additional imaging, biopsy, local treatment, or a systemic-treatment change. Do not stop Tagrisso without discussing the findings with your oncology team.
Comments